Caregiving in a time of coronavirus: A message from your Alzheimer’s Disease Research Center

Related posts:

1. From data to decision-making: the role of machine learning and digital twins in Alzheimer’s Disease For patients experiencing cognitive decline due to Alzheimer’s Disease (AD), choosing the most appropriate treatment course at the right time is of great importance. A key element to these decisions is the careful consideration of the available scientific evidence, particularly from randomized clinical trials (RCTs) such as the recent lecanemab...
2. FDA Approves Donanemab Today, the US Food and Drug Administration granted full clinical approval to Eli Lilly to market donanemab, brand name KISUNLA, for the treatment of early Alzheimer’s disease, including Mild Cognitive Impairment (MCI) or mild dementia. Donanemab is a monoclonal antibody against the beta-amyloid protein that accumulates in the brain of...
3. MIND Matters | Quarterly Newsletter | Summer 2024 ...